Clinical Trial Update: A Phase II Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy [Phase 2]

View source ↗

Summary

Phase II clinical trial evaluating HLX22 in combination with trastuzumab and chemotherapy for HER2-positive metastatic pancreatic ductal adenocarcinoma; the stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• HLX22
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Metastatic PDAC, HER2-positive Status | Phase 2 | Status: ACTIVE_NOT_RECRUITING